PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩300 per share · Prices as of the 2026-10-02 close
Bioinfra, Korea's leading bioequivalence (BE) test CRO by approval share, returned to a marginal consolidated profit in Q2 2026 after four straight quarterly losses, though the multi-year revenue decline and equity erosion have not yet reversed.
Q2 2026 consolidated operating profit of KRW 0.76 billion and owners' net income of about KRW 1.5 million mark a return to profit after four consecutive loss quarters.
Revenue fell for four straight years from KRW 35.4 billion (2022) to KRW 23.1 billion (2025), while operating margin deteriorated from +18.0% to -27.1%.
Accumulated net losses shrank equity from KRW 34.0 billion (2023) to KRW 16.5 billion (2025), while the debt ratio rose from 38.4% to 112.0%.
MFDS's planned expansion of mandatory BE testing to prescription generics from October 2026 is cited as a potential variable for earnings recovery.
The company is diversifying into drug quality control (QC) testing and immunoassay services for biologics such as antibody-drug conjugates (ADCs).
Bioinfra was founded in 2007 and listed on KOSDAQ in March 2023; it is headquartered in Yongin, Gyeonggi Province.
Its core businesses cover bioequivalence (BE) testing for generic drugs, Phase 1 clinical trials for improved new drugs, authorization-purpose clinical trials, immunoassay services, and drug quality control (QC) testing.
The company held a 23.6% share of Korea's BE test approvals as of 2021, ranking first, and counts major domestic pharmaceutical companies such as Chong Kun Dang, Yuhan, and Hanmi Pharm among its clients.
Its incurred sample reanalysis (ISR) accuracy of 96.7% is cited as higher than that of several overseas CRO peers with revenues above KRW 3 trillion. At the time of its listing, brokerages named domestic peers including BioToxTech and DreamCIS as comparable listed companies.
More recently, the company launched immunoassay and mass-spectrometry services targeting biologics such as antibody-drug conjugates (ADCs). It also invested KRW 4.5 billion to build a new testing center, entering Korea's drug QC market, estimated at more than KRW 50 billion.
The company additionally holds PCT patents in major jurisdictions for tube-opening devices and dispensing systems, underpinning its automation technology in sample analysis.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩6.1B | -₩1.1B | −18.4% |
| 2025Q3 | ₩5.1B | -₩2.1B | −40.5% |
| 2025Q4 | ₩6.6B | -₩900M | −13.7% |
| 2026Q1 | ₩5.5B | -₩2.4B | −43.8% |
| 2026Q2 | ₩8.5B | ₩75,712,698 | 0.9% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩35.4B | ₩6.4B | ₩6.2B | 18.0% | 34.8% | 82.0% |
| 2023 | ₩30.1B | ₩1.3B | ₩2B | 4.3% | 5.9% | 38.4% |
| 2024 | ₩23.8B | -₩5.1B | -₩4B | −21.5% | −14.4% | 49.2% |
| 2025 | ₩23.1B | -₩6.3B | -₩9.1B | −27.1% | −55.4% | 112.0% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-09-05
Consolidated revenue fell for four consecutive years, from KRW 35.4 billion in 2022 to KRW 30.1 billion (2023), KRW 23.8 billion (2024), and KRW 23.1 billion (2025).
Operating profit shrank from KRW 6.4 billion (18.0% margin) in 2022 to KRW 1.3 billion (4.3%) in 2023, before turning into losses of KRW 5.1 billion (-21.5%) in 2024 and KRW 6.3 billion (-27.1%) in 2025.
Net income attributable to owners also swung from profits of KRW 6.2 billion (2022) and KRW 2.0 billion (2023) to losses of KRW 4.0 billion (2024) and KRW 9.1 billion (2025). Equity fell from KRW 34.0 billion in 2023 to KRW 16.5 billion in 2025, while the debt ratio jumped from 38.4% to 112.0%.
Operating cash flow also deteriorated from +KRW 8.4 billion in 2022 to -KRW 1.5 billion in 2025, indicating weaker cash generation.
Quarterly, the company posted four consecutive operating losses from Q2 2025 through Q1 2026 (KRW -1.12 billion, -2.05 billion, -0.90 billion, and -2.41 billion, respectively), alongside net losses.
Notably, in Q4 2025 the net loss of KRW 3.58 billion was far larger than the operating loss of KRW 0.90 billion, suggesting non-operating items widened the gap.
Revenue then jumped to KRW 8.50 billion in Q2 2026 from KRW 5.50 billion in the prior quarter, with operating profit of KRW 0.076 billion and owners' net income of about KRW 1.5 million marking a marginal return to profit.
In a provisional standalone-basis disclosure, the company attributed the improvement to expanded BE-test and clinical-trial orders alongside stronger cost management.
In Korea's CRO industry, BE testing is a mandatory step for generic drugs to retain the same reimbursement price as the originator; without it, a generic's price can fall to as low as 38.69% of the originator's price.
The Ministry of Food and Drug Safety (MFDS) has progressively expanded the scope of mandatory BE testing and is now pursuing plans to include prescription generics as well. According to MFDS data, drugs subject to BE re-evaluation numbered 4,107 in 2024 and 1,601 in 2025.
This policy trend is cited as favorable for Bioinfra, the top domestic player by BE test approval count. In practice, however, order volumes have also been pressured as key biotech clients struggled to secure R&D funding, tempering the expected policy tailwind.
Several competitors, including BioToxTech and DreamCIS, operate in the domestic CRO space, keeping order competition active. As a result, the BE-testing market sits at the intersection of a structural regulatory growth driver and the funding conditions of biotech clients.
The company signaled a potential turnaround by posting a consolidated operating and net profit in Q2 2026. Management attributed the improvement to expanded BE-test and clinical-trial orders, increased sample-analysis services, and stronger cost management.
On the policy front, prescription generics are scheduled to be included in mandatory BE testing from October 2026, making order volume after implementation a key point to watch. Some observers note that test volumes could rise ahead of the deadline given Ministry of Health and Welfare data-submission timelines.
On the diversification front, whether the QC testing center—backed by a KRW 4.5 billion investment—and immunoassay services for biologics such as ADCs become meaningful new revenue streams remains a key point to monitor.
However, industry forecasts made in 2023 that anticipated policy-driven gains (projecting next-year revenue of about KRW 55.1 billion and operating profit of about KRW 11.2 billion) diverged sharply from actual results, underscoring the need to watch whether policy expectations translate into realized earnings this time.
With net losses persisting over the most recent four quarters (Q3 2025 through Q2 2026), a conventional price-to-earnings comparison is difficult to apply meaningfully. Shares trade at a discount relative to book value per share, a relationship linked to the erosion of equity from several years of accumulated losses.
At its 2023 listing, the IPO price was set using a price-to-earnings multiple of 11.7–13.7x based on that year's results, but current losses make an earnings-based comparison largely inapplicable today.
The company has continued paying a cash dividend even while posting net losses in 2024 and 2025, a fact that should be read alongside share price levels rather than in isolation. How valuation metrics are interpreted going forward will depend on whether the Q2 2026 return to profit continues into subsequent quarters.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-09-05
MFDS plans to include prescription generics in mandatory BE testing starting October 2026. Without the test, a generic's reimbursement price can fall to as low as 38.69% of the originator's price, giving pharmaceutical companies a strong incentive to commission testing.
As the top domestic player with a 23.6% share of BE test approvals as of 2021, Bioinfra is cited as a direct beneficiary of expanded testing volume.
Consolidated revenue in Q2 2026 rose sharply to KRW 8.50 billion from KRW 5.50 billion in the prior quarter, with both operating profit and owners' net income turning positive. This marked the first profitable quarter following four consecutive quarters of losses from Q2 2025 through Q1 2026. Management cited expanded orders and stronger cost management as contributing factors.
Bioinfra launched new immunoassay services targeting biologics such as antibody-drug conjugates (ADCs). It invested KRW 4.5 billion in a new testing center to enter Korea's drug QC market, estimated at more than KRW 50 billion.
It also holds PCT patents for tube-opening devices and dispensing systems, supporting its automation technology in sample analysis.
Consolidated revenue declined for four straight years, from KRW 35.4 billion in 2022 to KRW 23.1 billion in 2025. Operating margin also fell sharply from +18.0% in 2022 to -27.1% in 2025, reflecting a marked deterioration in profitability.
Despite policy expectations, order volume is said to have been pressured by funding difficulties among key biotech clients.
Accumulated net losses cut equity by more than half, from KRW 34.0 billion in 2023 to KRW 16.5 billion in 2025. Over the same period, the debt ratio rose from 38.4% to 112.0%, and operating cash flow worsened from +KRW 8.4 billion in 2022 to -KRW 1.5 billion in 2025. With a thinner financial buffer, continued investment in new businesses carries added funding pressure.
In 2023, the investment industry forecast next-year revenue of about KRW 55.1 billion and operating profit of about KRW 11.2 billion, citing policy tailwinds. Actual 2024 results, however, showed revenue of KRW 23.8 billion and an operating loss of KRW 5.1 billion, diverging sharply from those projections.
Some observers argue the sustainability of the recent Q2 return to profit should also be watched with similar caution.
Recent quarterly results have swung widely, from an operating loss of KRW 2.41 billion to an operating profit of KRW 0.076 billion, making it premature to conclude a trend reversal from a single profitable quarter.
In Q4 2025, the net loss of KRW 3.58 billion was notably larger than the operating loss of KRW 0.90 billion, pointing to volatility from non-operating items. The next several quarters will likely be important in gauging the direction of earnings.
The debt ratio rose from 38.4% in 2023 to 112.0% in 2025, and operating cash flow turned negative at KRW -1.5 billion in 2025. With equity already reduced, continued investment in new businesses such as QC testing and immunoassay could add to funding pressure. The balance between maintaining dividend payments and financial capacity also warrants monitoring.
Funding conditions among key biotech clients directly affect clinical-trial order volumes. Several competitors operate in Korea's CRO industry, keeping order competition ongoing. The speed and scale at which expanded regulatory mandates translate into actual revenue remain uncertain.
MFDS's mandatory BE testing for prescription generics is scheduled to take effect - watch for changes in test order volume and when revenue impact appears.
Check whether the Q3 2026 provisional results disclosure confirms continuation of the Q2 return to profit.
Review FY2026 annual revenue, operating profit, and equity changes to assess whether the multi-year decline in revenue and equity has reversed.
Watch for disclosure of revenue contribution and utilization rates from the KRW 4.5 billion QC testing center and new immunoassay/ADC services.
Bioinfra has maintained the top share of Korea's BE test approvals for years as a CRO specialist. Yet consolidated revenue declined for four straight years from 2022 through 2025, and operating margin deteriorated from +18.0% to -27.1% over the same period, reflecting a prolonged profitability decline.
In the process, equity was cut by more than half and the debt ratio nearly tripled, weakening the balance sheet alongside the income statement. Still, in Q2 2026 the company posted a consolidated operating profit and net profit, halting a four-quarter streak of losses.
Looking ahead, the planned October 2026 expansion of mandatory BE testing and new QC and immunoassay businesses are cited as potential variables for earnings.
However, given that policy-driven forecasts made in 2023 diverged sharply from actual results, whether the recent return to profit becomes a sustained trend will require confirmation over the next several quarters.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.